On the basis of these results and previous reports,21,22 we concluded that trametinib-induced short-term proliferation inhibition in KRAS-mutant NSCLC cells was attributed mainly to the inhibition of the MEK-ERK pathway. Here, MAP2K7 is linked to non-small cell lung carcinoma.